Moreover, in a double-blind phase III trial in patients with grade 2 IDH-mutant glioma (NCT04164901), vorasidenib, an inhibitor of mutant IDH1/2 enzymes, was shown to significantly improve progression-free survival compared with the placebo group (median progression-free survival, 27.7 versus 11.1 months) (275). Here, IDH1 is linked to glioma.